The results of an allergen POC trial in asthmatics will summarized by Dr. David Ramos, principal investigator of the PBF-680 clinical program, in an oral presentation titled:
PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: a Phase-IIa trial.
The study concluded that in mild-to-moderate asthmatics, PBF-680 abrogated the LAR, and reduced the EAR, FeNO, and, remarkably, blood eosinophils, with correct safety profile. The data position the adenosine modulator PBF-680 as a promising oral asthma therapy.
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
Un equipo de investigadores de la Universidad Juli...
En nuestro post hablamos sobre este interesante tipo de célula del...
Palobiofarma S.L. is pleased to announce the “last patient last visi...
Biotechnology portal in Spain
Subscribe to our newsletter and stay up to date with the latest news and deals!
2013 © Biotech-Spain.com - Site Developments SL. All Rights Reserved. Terms of Service | Privacy Policy
Articles
Directory